REPLICor's Antiviral Drug Is Active against H5N1 Avian Flu

REPLICor's lead compound, REP 9, has been shown to have potent antiviral activity against avian H5N1 influenza virus. The influenza virus used in the study was A/Vietnam/1203/04, a human pathogenic avian influenza isolated from a fatally infected patient. This virus is highly aggressive and replicates much more rapidly than normal strains of the influenza virus. This initial demonstration of REP 9 in vitro activity against H5N1 was generated in collaboration with Dr. Michael Holbrook at The University of Texas Medical Branch at Galveston in their level 4 biosafety facility. REP 9 has also recently been shown to have potent antiviral activity against influenza virus strains which are resistant to the action of Tamiflu(TM) and Relenza(TM). "Source":[ http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=18500067].

---

Related articles

Researchers sequence western H5N1 virus genomes - In a paper in the May issue of Emerging Infectious Diseases, an international team of researchers report the first ever large-scale sequencing of western genomes of the deadly avian influenza virus, H5N1 (19.4.2007)